



Public Health Administration

Joshua Dugas, MBA, REHS
Director

Jennifer Osorio, REHS
Interim Assistant Director

Michael A. Sequeira, M.D.
Health Officer

February 28, 2022

San Bernardino County COVID-19 Provider,

Thank you for your partnership as we continue to provide COVID-19 therapeutic treatments to our San Bernardino County communities.

Recently, the U.S. Food and Drug Administration announced a modification to the Emergency Use Authorization (EUA) for AstraZeneca's COVID-19 therapeutic, Evusheld. This includes a change to the dosing regimen as described below.

Evusheld should now be administered as an initial dose of 600 mg. Individuals who have already received the previously authorized initial dose of 300 mg should receive a second Evusheld dose as soon as possible.

Further recommendations will be made for the appropriate timing of redosing (e.g. a repeat dose with 150mg of tixagevimab and 150mg of cilgavimab at 3 months or 6 months after the initial dose) when more data becomes available.

Evusheld is a combination of two monoclonal antibodies (tixagevimab and cilgavimab) indicated for pre-exposure prophylaxis of COVID-19 in adults and pediatric patients (12 years and older weighing at least 40 kg):

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and
- Who are moderately to severely immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
- For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

The NIH COVID-19 Treatment Guidelines Panel recommends that [priority for use as pre-exposure prophylaxis](#) should be provided to individuals who are at the highest risk for severe COVID-19 infection. Please also refer to NIH COVID-19 Treatment Guidelines Panel [recommendations to assist with identifying high risk patients](#). The Department of Health and Human Services maintains an [online locator](#) of all therapeutics, including Evusheld, to further support in product access.

Please refer to the [updated EUA](#) for more information on the updated dosing regimen for Evusheld.

Thank you,

A handwritten signature in black ink that reads "Michael A. Sequeira MD".

Michael A. Sequeira, M.D.
Health Officer
Department of Public Health

BOARD OF SUPERVISORS

COL. PAUL COOK (RET.)
First District

JANICE RUTHERFORD
Second District

DAWN ROWE
Vice Chair, Third District

CURT HAGMAN
Chairman, Fourth District

JOE BACA, JR.
Fifth District

Leonard X. Hernandez
Chief Executive Officer